Total Payments
$894,400
2024 Payments
$70,000
Companies
3
Transactions
72
Payment Breakdown by Category
Consulting$484,600 (54.2%)
Research$299,000 (33.4%)
Other$110,800 (12.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $484,600 | 39 | 54.2% |
| Unspecified | $299,000 | 18 | 33.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $110,800 | 15 | 12.4% |
Payments by Type
General
$595,400
54 transactions
Research
$299,000
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Taiho Oncology, Inc. | $400,400 | 27 | $0 (2018) |
| Amicus Therapeutics, Inc. | $383,200 | 30 | $0 (2024) |
| Pacira Pharmaceuticals Incorporated | $110,800 | 15 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,000 | 6 | Amicus Therapeutics, Inc. ($70,000) |
| 2023 | $14,200 | 6 | Amicus Therapeutics, Inc. ($14,200) |
| 2022 | $106,000 | 10 | Amicus Therapeutics, Inc. ($106,000) |
| 2021 | $193,000 | 8 | Amicus Therapeutics, Inc. ($193,000) |
| 2020 | $110,800 | 15 | Pacira Pharmaceuticals Incorporated ($110,800) |
| 2018 | $296,400 | 20 | Taiho Oncology, Inc. ($296,400) |
| 2017 | $104,000 | 7 | Taiho Oncology, Inc. ($104,000) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/13/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 07/23/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $24,000.00 | General |
| 05/10/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $16,000.00 | General |
| 04/17/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,400.00 | General |
| 03/25/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $14,400.00 | General |
| 02/23/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,600.00 | General |
| 12/15/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: POMPE DISEASE | ||||||
| 12/14/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: POMPE DISEASE | ||||||
| 07/19/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: POMPE DISEASE | ||||||
| 05/02/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: POMPE DISEASE | ||||||
| 05/02/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: POMPE DISEASE | ||||||
| 03/22/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: POMPE DISEASE | ||||||
| 12/16/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $6,800.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 12/16/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $5,600.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 10/25/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $3,200.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 10/25/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 06/28/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $4,000.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 06/14/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $14,000.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 06/14/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $9,600.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 04/05/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $18,400.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 02/22/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $18,800.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 01/25/2022 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $24,000.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 12/22/2021 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $20,000.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 12/20/2021 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $20,000.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
| 10/19/2021 | Amicus Therapeutics, Inc. | — | — | Cash or cash equivalent | $28,000.00 | Research |
| Study: PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | Amicus Therapeutics, Inc. | $299,000 | 18 |
About Dr. Martin Bedigian, MD
Dr. Martin Bedigian, MD is a Internal Medicine healthcare provider based in Livingston, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2015. The National Provider Identifier (NPI) number assigned to this provider is 1336524263.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Bedigian, MD has received a total of $894,400 in payments from pharmaceutical and medical device companies, with $70,000 received in 2024. These payments were reported across 72 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($484,600).
Ad
Practice Information
- Specialty Internal Medicine
- Location Livingston, NJ
- Active Since 07/21/2015
- Last Updated 07/21/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336524263
Products in Payments
- Lonsurf (Drug) $400,400
- EXPAREL (Drug) $110,800
- POMBILITI (Drug) $14,200
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Livingston
Dr. Fariborz Rezai, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Dr. Sridhar Nambi, Md, MD
Internal Medicine — Payments: $152,292
Internal Medicine $152,292
Dr. Noah Rosenberg, Md, MD
Internal Medicine — Payments: $148,109
Internal Medicine $148,109
Dr. Bruce Haik, M.d, M.D
Internal Medicine — Payments: $32,109
Internal Medicine $32,109
Dr. Anna Litvak, Md, MD
Internal Medicine — Payments: $21,218
Internal Medicine $21,218
John Anton, M.d, M.D
Internal Medicine — Payments: $13,331
Internal Medicine $13,331